These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 14638779)

  • 1. Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses.
    Taracha EL; Bishop R; Musoke AJ; Hill AV; Gilbert SC
    Infect Immun; 2003 Dec; 71(12):6906-14. PubMed ID: 14638779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
    Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
    J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
    Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
    J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy.
    Tchilian E; Ahuja D; Hey A; Jiang S; Beverley P
    Vaccine; 2013 Sep; 31(41):4624-31. PubMed ID: 23896422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.
    Spencer AJ; Hill F; Honeycutt JD; Cottingham MG; Bregu M; Rollier CS; Furze J; Draper SJ; Søgaard KC; Gilbert SC; Wyllie DH; Hill AV
    PLoS One; 2012; 7(3):e33555. PubMed ID: 22470455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.
    Santosuosso M; McCormick S; Zhang X; Zganiacz A; Xing Z
    Infect Immun; 2006 Aug; 74(8):4634-43. PubMed ID: 16861651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
    McShane H; Pathan AA; Sander CR; Keating SM; Gilbert SC; Huygen K; Fletcher HA; Hill AV
    Nat Med; 2004 Nov; 10(11):1240-4. PubMed ID: 15502839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol.
    Cayabyab MJ; Kashino SS; Campos-Neto A
    Immunology; 2012 Mar; 135(3):216-25. PubMed ID: 22043824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis.
    Lee LN; Ronan EO; de Lara C; Franken KL; Ottenhoff TH; Tchilian EZ; Beverley PC
    Infect Immun; 2011 Aug; 79(8):3328-37. PubMed ID: 21628524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
    Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z
    J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
    Vordermeier HM; Villarreal-Ramos B; Cockle PJ; McAulay M; Rhodes SG; Thacker T; Gilbert SC; McShane H; Hill AV; Xing Z; Hewinson RG
    Infect Immun; 2009 Aug; 77(8):3364-73. PubMed ID: 19487476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A.
    Kirman JR; Turon T; Su H; Li A; Kraus C; Polo JM; Belisle J; Morris S; Seder RA
    Infect Immun; 2003 Jan; 71(1):575-9. PubMed ID: 12496215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis.
    West NP; Thomson SA; Triccas JA; Medveczky CJ; Ramshaw IA; Britton WJ
    Vaccine; 2011 Oct; 29(44):7759-65. PubMed ID: 21846485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ag85A-specific CD4
    Metcalfe HJ; Biffar L; Steinbach S; Guzman E; Connelley T; Morrison I; Vordermeier HM; Villarreal-Ramos B
    Vaccine; 2018 May; 36(20):2850-2854. PubMed ID: 29655632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.
    Hoft DF; Blazevic A; Stanley J; Landry B; Sizemore D; Kpamegan E; Gearhart J; Scott A; Kik S; Pau MG; Goudsmit J; McClain JB; Sadoff J
    Vaccine; 2012 Mar; 30(12):2098-108. PubMed ID: 22296955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.